Oncology Innovations: Key Trial Data and AI at ESMO 2024
Groundbreaking Trial Data Presented at ESMO 2024
Across 5 days, the ESMO Congress 2024 will present practice-changing trial data, encouraging early-stage trial data, innovative approaches to cancer care and research, and more. The meeting will be held both virtually and in person from September 13-17 in Barcelona, Spain.
- Summary of Key Presentations: In total, the Congress will offer 86 late-breaking abstracts.
- Phase 3 Results: Significant studies include:
- EORTC-GUCG 1333/PEACE-3: Enzalutamide in prostate cancer patients.
- POD1UM-303/InterAACT 2: Retifanlimab with carboplatin-paclitaxel in anal cancer.
- LEAP-012: Transarterial chemoembolization's outcomes in liver cancer.
- EGOT-cx11/GOG-3047/KEYNOTE-A18: Pembrolizumab in cervical cancer.
- Oncofertility Sessions: Highlighting fertility preservation amid treatment.
- Antibody-Drug Conjugates (ADCs): Fostering advancements in cancer therapies.
- Young-Onset Cancers: Important sessions exploring colorectal cancer and external factors.
Technology's Role in Cancer Care
A session will evaluate how technology assists in gynecological cancer care, with a specific focus on applications of artificial intelligence in oncology.
Dr. Amy Abernethy will present on implementing AI at scale in oncology, focusing on precision oncology. Abernethy's experience with the FDA and Verily brings a wealth of knowledge to these discussions.
Continuing Education and Insights
The Congress concludes with sessions highlighting breast cancer, policy advancements, and new strategies in immunotherapy.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.